Dihexa: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •3 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
Dihexa potentiates the HGF/c-Met signaling pathway, which is a well-established driver of tumor growth, invasion, and metastasis. No carcinogenicity studies have been conducted.
No human clinical trials have been conducted. The side effect profile, maximum tolerated dose, drug interactions, and long-term safety in humans are completely unknown.
A key 2014 mechanistic study was retracted due to data fabrication by the original investigators, weakening the evidence base for the proposed mechanism of action.
⚠️Important Warnings
- •NOT APPROVED FOR HUMAN USE: Dihexa has not been evaluated in human clinical trials and is not approved by any regulatory agency for any therapeutic indication.
- •ONCOGENIC RISK: The c-Met/HGF pathway is a well-established driver of cancer biology. Sustained potentiation of this pathway carries theoretical oncogenic risk. Individuals with cancer or precancerous conditions should not use this compound.
- •DATA INTEGRITY: A key mechanistic study (Benoist et al., 2014) was retracted due to data fabrication, reducing confidence in the proposed mechanism of action.
- •NO SAFETY DATA: Long-term safety has not been established in any species. Reproductive toxicity, carcinogenicity, and genotoxicity studies have not been conducted.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Unscheduled | Not FDA-approved. Not a controlled substance. Available as a research chemical. Not approved for human consumption. |
| United Kingdom | Unscheduled | Not approved by MHRA for any therapeutic use. May be available for research purposes. |
| Canada | Unscheduled | Not approved by Health Canada. Not a controlled substance. Available for research purposes only. |
| European Union | Unscheduled | Not approved by EMA. Regulatory status varies by member state. Generally available as a research chemical. |
| Australia | Unscheduled | Not approved by TGA. Not specifically scheduled. May require import permits for research use. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 45+ community reports
View community protocolsCritical Safety Information#
Dihexa (PNB-0408) is not approved for human use by any regulatory agency worldwide. It has not undergone human clinical trials. All efficacy data comes from animal studies, and a key mechanistic study has been retracted due to data integrity concerns. The information below outlines the known and theoretical risks.
Primary Risks#
Oncogenic Risk (Theoretical but Significant)#
The HGF/c-Met signaling pathway that dihexa potentiates is one of the most well-characterized oncogenic pathways in cancer biology. Multiple pharmaceutical companies have developed c-Met inhibitors specifically because excessive c-Met signaling drives tumor progression:
- c-Met activation promotes cell proliferation, survival, motility, invasion, and angiogenesis
- HGF/c-Met dysregulation is implicated in lung, liver, gastric, breast, and other cancers
- FDA-approved drugs capmatinib and tepotinib work by blocking the same pathway dihexa activates
While dihexa potentiates rather than constitutively activates c-Met, and its effects may be limited to the presence of endogenous HGF, no carcinogenicity studies have been conducted to evaluate this risk.
Complete Absence of Human Safety Data#
There are no:
- Phase 1 safety or dose-finding studies
- Pharmacokinetic profiles in humans
- Maximum tolerated dose determinations
- Drug-drug interaction studies
- Special population studies (renal impairment, hepatic impairment, elderly, pediatric)
- Reproductive or developmental toxicity studies
Data Integrity Concerns#
The Benoist et al. (2014) study in the Journal of Pharmacology and Experimental Therapeutics was the primary evidence linking dihexa's cognitive effects to HGF/c-Met-dependent synaptogenesis. This study was retracted after Washington State University found that figures and data were falsified and/or fabricated by Kawas and Harding. While other studies partially support dihexa's cognitive effects, the retraction weakens the overall evidence base.
Legal and Regulatory Status#
Dihexa is not a controlled substance in any major jurisdiction. It is not approved for therapeutic use anywhere in the world. It is classified as a research chemical and is available through chemical suppliers for in vitro and animal research purposes.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Not approved, not controlled | Research chemical; not for human consumption |
| United Kingdom | Not approved | Available for research purposes |
| Canada | Not approved | Research chemical classification |
| European Union | Not approved | Status varies by member state |
| Australia | Not approved | May require import permits |
Risk Mitigation#
Given the preclinical status and theoretical risks, the following considerations apply:
For Researchers#
- All animal research should follow institutional review board and IACUC protocols
- Carcinogenicity and genotoxicity assessment should precede any consideration of human studies
- Independent replication of key findings is needed given the retraction history
For the Public#
- Dihexa is not approved for self-administration
- No evidence supports safe use in humans
- The oncogenic risk profile makes this compound particularly concerning for unsupervised use
- Individuals with any cancer history should be especially cautious
Related Reading#
Frequently Asked Questions About Dihexa
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.